biostudies-literatureUnknown13(6)Zschabitz SProstate specific membrane antigen (PSMA) is an emerging diagnostic and therapeutic target in prostate cancer. ⁶⁸Ga-PSMA-labeled hybrid imaging is used for the detection of prostate primary tumors and metastases. Therapeutic applications such as Lutetium-177 PSMA radionuclide therapy or bispecific antibodies that target PSMA are currently under investigation within clinical trials. The expression of PSMA, however, is not specific to prostate-tissue. It has been described in the neovascular endothelium of different types of cancer such as breast cancer, and clear cell renal cell carcinoma (ccRCC). The aim of this study was to analyze PSMA expression in papillary RCC (pRCC) type 1 and type 2, the most common non-ccRCC subtypes, and to evaluate the potential of PSMA-targeted imaginJournal of Cancer1706-1712https://www.ebi.ac.uk/biostudies/studies/S-EPMC8990413biostudies-literatureExpression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.PMC8990413Stief CTrojan LRoos FCStrobel PBarth PStockle MOtto WStaehler MNoldus JWulfing CIvanyi PHaferkamp AErlmeier FStohr CWalter BMacher-Goppinger SZschabitz SHerrmann EBurger MHartmann APolifka IBrenner WSteffens SAgaimy AHohenfellner MBecker FSchrader AJWullich BMondorf YfalseExpression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.Prostate specific membrane antigen (PSMA) is an emerging diagnostic and therapeutic target in prostate cancer. ⁶⁸Ga-PSMA-labeled hybrid imaging is used for the detection of prostate primary tumors and metastases. Therapeutic applications such as Lutetium-177 PSMA radionuclide therapy or bispecific antibodies that target PSMA are currently under investigation within clinical trials. The expression of PSMA, however, is not specific to prostate-tissue. It has been described in the neovascular endothelium of different types of cancer such as breast cancer, and clear cell renal cell carcinoma (ccRCC). The aim of this study was to analyze PSMA expression in papillary RCC (pRCC) type 1 and type 2, the most common non-ccRCC subtypes, and to evaluate the potential of PSMA-targeted imagin2022-01-01T00:00:00Z20222025-04-18T16:41:39.517Z2024-11-15T00:48:13.106ZS-EPMC89904133539971510.7150/jca.63509